Wijsenbeek [13] | Netherlands | 52 | Age: 63.4±7.7 years Baseline FVC (% pred): 68.3±18.4 | Stable lung function in 17 out of 20 patients treated for >6 months (three out of 20 declined). In 11 out of 19 patients cough score decreased (unchanged: n=7; increased: n=1) | NA | NA | 19 |
Ravaglia [14] | Italy | 81# | Age: 69 (41–81) years Baseline FVC (% pred): 70.8 | Stable or significantly improved lung function in 40 (59%) out of 68 patients | NA | NA | 16 |
Nieto Barbero [15] | Spain | 86 | Age: NA Baseline FVC (% pred): 70±19 | Stable FVC and DLCO in those who had pulmonary function testing (n=20) | 35 (41) | 11 (13)+ | 14 |
Bonella [16] | Germany | 45 | Age: 69±7 years Baseline FVC (% pred):
61±15 | Stable lung function in 28 (70%) out of 40 patients; subjective improvement in cough in 12 (33%) out of 36 patients | 17 (38) | 10 (22) | 13 |
Okuda [17] | Japan | 76 | Age: 70.5±8.3 years Baseline FVC (% pred): 65.3±16.1 | Reduction in FVC and DLCO decline | 18 (24)§ | 19 (25)ƒ | 18 |
Arai [18] | Japan | 41 | Age: 70 (65.5–75.5) years Baseline FVC (% pred): 66.7 (54.8–77.8)¶ | Significant reduction in vital capacity decline in patients with severity grades I–II (Japanese Respiratory Society criteria) | 24 (59)## | 5 (12)+ | 15 |
Oltmanns [19] | Germany | 63 | Age: 68±7 years Baseline FVC (% pred): 70±19 | Stable lung function in 62% of patients | NA | NA | 13 |
Chaudhuri [20] | UK | 40 | Age: 65.8 (48–80) years Baseline FVC (% pred): 77.3 (46–146) | Reduction in FVC and DLCO decline at 9 months | 87 | 10+ | 15 |